Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 5/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600822 | 0.91 | GRIN2B (0.50) | STSRORCGPR119OPRD1OPRK1 | |
| SCHEMBL2993411 | 0.89 | OPRD1 (0.48) | STSRORCGPR119OPRD1OPRK1 | |
| SCHEMBL25410856 | 0.88 | SCD5 (0.46) | STSRORCGPR119OPRD1OPRK1 | |
| SCHEMBL20858795 | 0.87 | STS (0.44) | STSRORCGPR119OPRD1OPRK1 | |
| SCHEMBL2951728 | 0.86 | OPRD1 (0.53) | STSGPR119OPRD1OPRK1KDM4E | |
| SCHEMBL25133343 | 0.86 | GPR119 (0.49) | GPR119OPRD1OPRK1JAK2JAK1 | |
| SCHEMBL24362417 | 0.86 | RORC (0.49) | RORCGPR119JAK2JAK1 | |
| SCHEMBL26986851 | 0.84 | STS (0.46) | STSRORCGPR119OPRD1OPRK1 | |
| SCHEMBL13452646 | 0.84 | SMN1; SMN2 (0.47) | STSGPR119OPRD1OPRK1JAK2 | |
| SCHEMBL17726836 | 0.82 | MEN1 (0.48) | STSGPR119OPRD1OPRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9388164-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388164-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388164-B2 | Methods of using pyruvate kinase activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9221792-B2 | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators | AGIOS PHARMACEUTICALS, INC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221792-B2 | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators | AGIOS PHARMACEUTICALS, INC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221792-B2 | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators | AGIOS PHARMACEUTICALS, INC (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2651898-B1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL)PHENYL)-(HETERO-)ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014074848-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074848-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2651898-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | Agios Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012151448-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151448-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012083246-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083246-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | PDK2, PDK3, PDK4 | STS 2032/4885RORC 3273/4885GPR119 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.